$TPST

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors September 23, 2026 Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies BRISBANE, Calif., Sept. 23, 2026 (GLOBE

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform -Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

DataMEDS AI (MEDS) rose 295.53% after acquiring Helomics for $1.5M, expanding into precision oncology. Tempest Therapeutics (TPST) gained 58.86% with a CAR-T licensing deal. NeurAxis (NRXS) increased 22.63% on expanded insurance coverage for its PENFS therapy. MAIA Biotechnology (MAIA) rose 5.22% after dosing the first U.S. patient in its THIO-101 trial.

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On September 15, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order

Tempest Therapeutics (NASDAQ:TPST) shares rose 21% after announcing an exclusive option agreement with Hebei Senlang Biotechnology to license Senlang’s CD7-targeted lentiviral vector platform, including a Phase 1 BCMA/GPRC5D dual-targeting candidate for multiple myeloma. The deal complements Tempest’s existing in vivo CAR-T platform, set to enter clinical trials later this year.

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement On September 11, 2026, Tempest Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Investor ”), pur

Tempest Therapeutics (TPST) announced a private placement of 3.1M shares and warrants, raising $2.5M, with potential additional proceeds of $5M if warrants are exercised. Proceeds will be used for working capital. The offering is expected to close on September 14, 2026, subject to conditions.

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Financial and Accounting Officer On August 18, 2026, Mr. Justin Trojanowski notified Tempest Therape

Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. Item 8.01 Other Events. On August 17, 2026, Tempest Therapeutics, Inc. (the “Company”) called to order its

Tempest Therapeutics (TPST) reported Q2 2026 net loss of $5.2M, or $0.34/share, versus $7.9M, or $2.07/share a year earlier. R&D fell to $1.8M and G&A to $3.4M. Cash was $0.8M at June 30. The company advanced TPST-4003 (CD19/BCMA via CD7 mRNA/LNP) with a Senlang collaboration and a China investigator trial starting Q4 2026, and cited interim TPST-2003 data. Shares were up in premarket.